The 2011 Oriental Inflammatory Bowel Disease Forum was held at Shanghai Sheraton Hotel from 24 to 26 June 2011. CMS obtained a number of sponsorship of this conference and also took this opportunity to improve expert network in the IBD field in China. In the meeting of 24 June, the group leader of the IBD research team affirmed the excellent effectiveness of Salofalk for the treatment of inflammatory bowel disease, and also started the national multi-center clinical study of effectiveness and safety of mesalazine (Salofalk) enema for the treatment of ulcerative colonitis, and also determined the clinical research protocol of the enema. The conference expanded the influence of Salofalk nationwide and also established good brand image of this product.